SNPMiner Trials: Clinical Trial Report
Report for Clinical Trial NCT00400387
Developed by Shray Alag, 2019.
SNP Clinical Trial Gene
With this clinical trial the investigators will analyze whether the rate of pregnancy losses
before the 24th week of gestation can be reduced by dalteparin treatment in habitual
aborters.
NCT00400387 Abortion, Habitual
2 Interventions
Name: Fragmin P Forte (dalteparin sodium)
Description: subcutaneous injection, once daily supported by multivitamine supplement and close monitoringType: Drug
Multivitamin supplement + dalteparin sodium
Name: Multivitamin supplement
Description: general pregnancy support by multivitamin supplementation and close monitoringType: Dietary Supplement
Multivitamin supplement
Primary Outcomes
Measure: ongoing intact pregnancy at 24 weeks of gestation
Time: at 24 weeks of gestation
Secondary Outcomes
Measure: late pregnancy complication, defined as at least one of the following: preterm delivery, placenta insufficiency, intrauterine growth retardation, preeclampsia and abruptio placentae
Time: 6-8 weeks after delivery
Measure: foetus with structural anomalies
Time: 6-8 weeks after delivery
Measure: side effects of dalteparin therapy (e.g. thrombocytopenia, osteoporosis, haemorrhage)
Time: 6-8 weeks after delivery
Measure: life birth
Time: 6-8 weeks after delivery
Measure: preterm delivery (< 37 weeks of gestation)
Time: 6-8 weeks after delivery
Purpose: Treatment
Allocation: Randomized
Parallel Assignment
There is one SNP
SNPs
Likewise, other thrombophilic risk factors including factor II G20210A, hyperhomocysteinemia,
protein C, protein S and antithrombin deficiencies have also been associated with RPL (Sanson
1996; Brenner 1999). --- G20210A ---
HPO Nodes